REDWOOD CITY, Calif.,
Aug. 30, 2013 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and CEO, will present a corporate overview
at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel
in Boston, MA. The
presentation is scheduled for Wednesday,
September 11, 2013 at 9:45 a.m.
ET/6:45 a.m. PT.
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay of the
presentations will be archived for 90 days and available through
the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. Zalviso has successfully completed all three of its
planned Phase 3 clinical trials and a New Drug Application
submission is planned for the third quarter of 2013. AcelRx
has announced positive top-line results for a Phase 2 trial for
ARX-04, a sufentanil formulation for the treatment of
moderate-to-severe acute pain, funded through a grant from U.S.
Army Medical Research and Materiel Command. The company has
two additional pain treatment product candidates, ARX-02 and
ARX-03, which have completed Phase 2 clinical development.
For additional information about AcelRx's clinical programs please
visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to the process
and timing of anticipated future clinical development of AcelRx
Pharmaceuticals' product candidates, the potential submission of an
NDA for Zalviso and the timing thereof, therapeutic and commercial
potential of Zalviso and the anticipated timing and therapeutic and
commercial potential of other AcelRx product candidates.
These forward-looking statements are based on AcelRx's
current expectations and inherently involve significant risks and
uncertainties. AcelRx's actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
the success, cost and timing of AcelRx's product development
activities and clinical trials; any delays or inability to obtain,
regulatory approval of its product candidates; its ability to
obtain adequate clinical supplies of the drug and device components
of its product candidates; its ability to attract funding partners
or collaborators with development, regulatory and commercialization
expertise; its ability to obtain sufficient financing to complete
development and registration of its product candidates in
the United States and Europe; its ability to obtain and maintain
regulatory approvals of its product candidates; the market
potential for its product candidates; the accuracy of AcelRx's
estimates regarding expenses, capital requirements and needs for
financing; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission
filings and reports, including its Quarterly Report on Form 10-Q
for the three months ended June 30,
2013, filed August 12, 2013.
AcelRx undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.
(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.